TCTR20110000018招募中3 期
Topical Bevacizumab 0.05% Eye Drops for Preventing Recurrent Pterygium, A Randomized, Double-masked, Controlled Trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •* Patients who are diagnosed with primary pterygium and plan for pterygium excision with bare sclera by single surgeon. (G.N.)
- •* Patients with pterygium who understand and can follow the study protocol.
- •* Patients of age more than 30 years
排除标准
- •* Patients who have corneal melt, corneal epitheliopathy, abnormal corneal epithelial wound healing.
- •* Patients who are pregnancy or lactation.
- •* Patients who have a history of allergy to bevacizumab.
- •* Patients who have a history of allergy to steroid eye drops
研究者
相似试验
已完成
3 期
Topical Bevacizumab for Preventing Recurrent PterygiumBevacizumabVEGFAnti-VEGFPterygiumNCT01311960Chulalongkorn University24
尚未招募
2 期
Role of subconjunctival injection of Bevacizumab (Anti VEGF) for Corneal Neovascularisation,after cornea TransplantCTRI/2021/10/037416SNMedical College
Unknown
2 期
Bevacizumab for the Treatment of Corneal NeovascularizationCorneal NeovascularizationNCT00992849Chang Gung Memorial Hospital10
招募中
不适用
Treatment with bevacizumab for ocular vascular lesionsOcular vascular lesionsJPRN-UMIN000020916Keio University, School of Medicine1,000
已完成
不适用
Intravitreal bevacizumab injection for intraocular neovascularization in childreRetinopathy of prematurityJPRN-UMIN000014316Kansai Medical University15